Pharma Equity Group A/S

Pharma Equity Group A/S FCF/Debt

The Free Cash Flow to Debt Ratio of Pharma Equity Group A/S (PEG.CO) as of Oct 22, 2026 is -438.51 %. In the previous year, Free Cash Flow to Debt Ratio was -206.98 % — a change of 111.86% (lower).

FCF/Debt

-438.51 %

YoY

111.86%

Last updated:

Free Cash Flow to Debt Ratio of Pharma Equity Group A/S is 2025 -438.51 % . Free Cash Flow to Debt Ratio of Pharma Equity Group A/S was 2024 -206.98 % . It decreases by 111.86% lower compared to the previous year.

The Pharma Equity Group A/S FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-106.26 DKK
Jan 1, 2019
-139.83 DKK
Jan 1, 2020
-98.65 DKK
Jan 1, 2021
-11.04 DKK
Jan 1, 2022
-12.58 DKK
Jan 1, 2023
-55.25 DKK
Jan 1, 2024
-206.98 DKK
Jan 1, 2025
-438.51 DKK
The Pharma Equity Group A/S FCF/Debt history
YEARFCF/DebtYoY
-438.51 %+111.86%
-206.98 %+274.63%
-55.25 %+339.09%
-12.58 %+13.99%
-11.04 %-88.81%
-98.65 %-29.45%
-139.83 %+31.60%
-106.26 %-97.78%
-4,777.67 %+188,578.37%
-2.53 %-80.00%
-12.66 %-99.96%
-32,000.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharma Equity Group A/S stock

Free Cash Flow to Debt Ratio of Pharma Equity Group A/S is -438.51 % in 2025.

Free Cash Flow to Debt Ratio of Pharma Equity Group A/S changed from -206.98 % to -438.51 %, representing a 111.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Pharma Equity Group A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Pharma Equity Group A/S

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Pharma Equity Group A/S